Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

1.2K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.2K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

810
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
810
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

116
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
116
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

297
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
297
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

64
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
64
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.3K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shifting Demographics and Polysubstance Drivers of Overdose Mortality in Pennsylvania (1999-2020).

Cureus·2026
Same author

Distinct Plasmodium falciparum Erythrocyte Membrane Protein 1 Domain Cassette-Associated Antibody Gaps Specific to Cerebral Malaria and Severe Malarial Anemia.

The Journal of infectious diseases·2026
Same author

EPR26-161: Risk for Anal Cancers in Hidradenitis Suppurativa Patients With Anorectal Fistulas or Abscesses: A Retrospective Cohort Study.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

EPR26-161: Risk for Anal Cancers in Hidradenitis Suppurativa Patients With Anorectal Fistulas or Abscesses: A Retrospective Cohort Study.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Isolated Gastrointestinal Kaposi's Sarcoma: A Case Report.

Journal of community hospital internal medicine perspectives·2026
Same author

In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y.

Annals of internal medicine·2026

Related Experiment Video

Updated: Sep 23, 2025

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.6K

Pseudohyperkalemia Associated With Leukemia.

Biraj Shrestha1, Swarup Sharma Rijal1, Arpan Pokhrel1

  • 1Internal Medicine, Reading Tower Health, Reading, USA.

Cureus
|May 11, 2022
PubMed
Summary

Falsely elevated serum potassium in leukemia patients can occur due to sample collection and processing errors. Rapid point-of-care testing is recommended to accurately distinguish true hyperkalemia from pseudohyperkalemia.

Keywords:
hyperkalemiaiatrogenic complicationsleukemiapoint-of-care testingpseudo hyperkalemia

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.2K

Related Experiment Videos

Last Updated: Sep 23, 2025

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.6K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.2K

Area of Science:

  • Clinical Chemistry
  • Hematology
  • Medical Diagnostics

Background:

  • Elevated serum potassium (hyperkalemia) is a critical medical emergency.
  • Leukemia patients present unique challenges in accurate electrolyte measurement.
  • Pseudohyperkalemia can mimic true hyperkalemia, leading to unnecessary interventions.

Observation:

  • A case of falsely elevated serum potassium in a leukemia patient was identified.
  • The patient was asymptomatic with a normal electrocardiogram (EKG), raising suspicion for pseudohyperkalemia.
  • Potential causes in leukemia patients include tourniquet use, pneumatic tube transport, prolonged incubation, heparin use, and centrifugation.

Findings:

  • Sample collection and processing methods are key contributors to pseudohyperkalemia in leukemia.
  • Rapid point-of-care testing (POCT) is a validated tool for differentiating false from true potassium elevations.
  • POCT shows good correlation with central laboratory analyzers for potassium levels above 3 mEq/L.

Implications:

  • Accurate potassium measurement is crucial for timely and appropriate patient management.
  • Implementing POCT can improve diagnostic accuracy and reduce patient risk in cases of suspected hyperkalemia.
  • Understanding pre-analytical variables is essential for reliable laboratory results in hematology patients.